非西班牙裔黑人与非西班牙裔白人美国退伍军人中前列腺特异性抗原筛查与前列腺癌死亡率的相关性
这项回顾性队列研究纳入45 834名55至69岁、2004年1月1日至2017年12月31日确诊为中危、高危或极高危前列腺癌的非西班牙裔黑人或白人退伍军人,评估PSA筛查率与前列腺癌特异性死亡率(PCSM)的关系。PSA筛查率与黑人(sHR 0.56;95%CI 0.41-0.76;P=0.001)和白人(sHR 0.58;95%CI 0.46-0.75;P=0.001)PCSM风险降低相关;年度筛查(对比部分筛查)与黑人PCSM风险显著降低相关(sHR 0.65;95%CI 0.46-0.92;P=0.02),白人则无显著差异(sHR 0.91;95%CI 0.74-1.11;P=0.35)。作者认为年度筛查对黑人可能尤为重要,需进一步研究确定合适人群和方案。
要点
- PSA筛查率与黑人PCSM风险降低相关(sHR 0.56;95%CI 0.41-0.76;P=0.001)。
- PSA筛查率与白人PCSM风险降低相关(sHR 0.58;95%CI 0.46-0.75;P=0.001)。
- 年度筛查对比部分筛查,黑人PCSM风险显著降低(sHR 0.65;95%CI 0.46-0.92;P=0.02),白人无显著差异(sHR 0.91;95%CI 0.74-1.11;P=0.35)。
核心结论
- 在该队列研究中,PSA筛查与非西班牙裔黑人和非西班牙裔白人男性PCSM风险降低相关。
- 年度筛查与黑人PCSM风险降低相关,但与白人无显著相关,提示年度筛查对黑人可能尤为重要。
- 需进一步研究确定合适人群和方案以最大化PSA筛查获益。
研究设计与样本
- 回顾性队列研究,使用美国退伍军人健康管理局信息与计算基础设施数据。
- 纳入55至69岁自认非西班牙裔黑人或非西班牙裔白人、2004年1月1日至2017年12月31日确诊为中危、高危或极高危前列腺癌的男性。
- 共纳入45 834名退伍军人,平均(SD)年龄62.7(3.8)岁,其中非西班牙裔黑人14 310人(31%),非西班牙裔白人31 524人(69%)。
- 数据分析时间为2021年8月至2022年3月。
主要发现
- PSA筛查率与黑人PCSM风险降低相关(sHR 0.56;95%CI 0.41-0.76;P=0.001)。
- PSA筛查率与白人PCSM风险降低相关(sHR 0.58;95%CI 0.46-0.75;P=0.001)。
- 亚组分析中,年度筛查对比部分筛查与黑人PCSM风险显著降低相关(sHR 0.65;95%CI 0.46-0.92;P=0.02)。
- 亚组分析中,年度筛查对比部分筛查与白人PCSM风险无显著相关(sHR 0.91;95%CI 0.74-1.11;P=0.35)。
关键数值与推荐
- PSA筛查率定义为诊断前列腺癌前5年内进行PSA筛查的年数百分比。
- 按诊断前5年内无既往PSA筛查、部分筛查(低于每年)或年度筛查分类评估PCSM风险。
- 主要结局为黑人和白人男性的PCSM风险,采用Fine-Gray回归分析评估PSA筛查与PCSM风险的关联。
临床怎么用
- 作者认为,年度筛查对黑人可能尤为重要。
- 作者指出需进一步研究确定合适人群和方案以最大化PSA筛查获益。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Black men have higher prostate cancer incidence and mortality than non-Hispanic White men. However, Black men have been underrepresented in clinical trials of prostate-specific antigen (PSA) screening; thus, there is a lack of data to guide screening recommendations for this population. OBJECTIVE: To assess whether PSA screening is associated with reduced risk of prostate cancer-specific mortality (PCSM) among non-Hispanic Black men. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study used data from the US Veterans Health Administration Informatics and Computing Infrastructure for men aged 55 to 69 years who self-identified as non-Hispanic Black or non-Hispanic White and were diagnosed with intermediate-, high-, or very high-risk prostate cancer from January 1, 2004, to December 31, 2017. Data were analyzed from August 2021 to March 2022. EXPOSURES: Prostate-specific antigen screening rate, defined as the percentage of years in which PSA screening was conducted during the 5 years before diagnosis of prostate cancer. MAIN OUTCOMES AND MEASURES: The primary outcome was risk of PCSM among Black men and White men. The association between PSA screening and risk of PCSM was assessed using Fine-Gray regression analysis. Risk of PCSM was also assessed categorically among patients classified as having no prior PSA screening, some screening (less than annual), or annual screening in the 5 years before diagnosis. RESULTS: The study included 45 834 veterans (mean [SD] age, 62.7 [3.8] years), of whom 14 310 (31%) were non-Hispanic Black men and 31 524 (69%) were non-Hispanic White men. The PSA screening rate was associated with a lower risk of PCSM among Black men (subdistribution hazard ratio [sHR], 0.56; 95% CI, 0.41-0.76; P = .001) and White men (sHR, 0.58; 95% CI, 0.46-0.75; P = .001). On subset analysis, annual screening (vs some screening) was associated with a significant reduction in risk of PCSM among Black men (sHR, 0.65; 95% CI, 0.46-0.92; P = .02) but not among White men (sHR, 0.91; 95% CI, 0.74-1.11; P = .35). CONCLUSIONS AND RELEVANCE: In this cohort study, PSA screening was associated with reduced risk of PCSM among non-Hispanic Black men and non-Hispanic White men. Annual screening was associated with reduced risk of PCSM among Black men but not among White men, suggesting that annual screening may be particularly important for Black men. Further research is needed to identify appropriate populations and protocols to maximize the benefits of PSA screening.
引用
- Sherer MV, Qiao EM, Kotha NV, et al. Association Between Prostate-Specific Antigen Screening and Prostate Cancer Mortality Among Non-Hispanic Black and Non-Hispanic White US Veterans. JAMA Oncol. 2022. PMID: 35925581. doi:10.1001/jamaoncol.2022.2970
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。